Larvol Delta - Biomind-Labs-Receives-Approval-for-a-Third-Phase-II-Clinical-Trial-for-Its-5MeODMT-Based-BMND08-Candidate-for-Treatment-of-Depression-and-Anxiety-in-Alzheimers-Disease

5-methoxy-N,N-dimethyltryptamine (BMND08) - Biomind

https://www.businesswire.com/news/home/20220526005075/en/Biomind-Labs-Receives-Approval-for-a-Third-Phase-II-Clinical-Trial-for-Its-5-MeO-DMT-Based-BMND08-Candidate-for-Treatment-of-Depression-and-Anxiety-in-Alzheimer%E2%80%99s-Disease

May 26, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next